Here are the latest quarterly results of Dishman Pharma. For more details, see the Dishman Pharma financial fact sheet and Dishman Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-15* |
3
Sep-15* |
3
Dec-15* |
3
Mar-16* |
3
Jun-16* |
3
Sep-16* |
3
Dec-16* |
3
Mar-17* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 4,005 | 3,812 | 3,887 | 4,221 | 3,754 | 4,366 | 3,621 | 5,342 | |
Other income | Rs m | 41 | 76 | 17 | 130 | 70 | 77 | 155 | 38 | |
Turnover | Rs m | 4,047 | 3,888 | 3,904 | 4,351 | 3,824 | 4,442 | 3,776 | 5,380 | |
Expenses | Rs m | 2,961 | 2,897 | 2,787 | 3,175 | 2,732 | 3,208 | 2,664 | 3,875 | |
Gross profit | Rs m | 1,044 | 915 | 1,100 | 1,046 | 1,022 | 1,158 | 953 | 1,462 | |
Depreciation | Rs m | 259 | 261 | 271 | 299 | 285 | 309 | 293 | 570 | |
Interest | Rs m | 319 | 236 | 185 | 205 | 225 | 189 | 134 | 101 | |
Profit before tax | Rs m | 507 | 494 | 661 | 672 | 583 | 736 | 682 | 829 | |
Tax | Rs m | 130 | 129 | 191 | 174 | 127 | 190 | 175 | 401 | |
Profit after tax | Rs m | 378 | 365 | 469 | 498 | 455 | 547 | 507 | 428 | |
Gross profit margin | % | 26.1 | 24.0 | 28.3 | 24.8 | 27.2 | 26.5 | 26.3 | 27.4 | |
Effective tax rate | % | 25.6 | 26.1 | 29.0 | 25.8 | 21.9 | 25.8 | 25.7 | 48.4 | |
Net profit margin | % | 9.4 | 9.6 | 12.1 | 11.8 | 12.1 | 12.5 | 14.0 | 8.0 | |
Diluted EPS | Rs | 2.3 | 2.3 | 2.9 | 3.1 | 2.8 | 3.4 | 3.1 | 2.7 | |
Diluted EPS (TTM) | Rs | 8.3 | 8.5 | 9.9 | 10.6 | 11.1 | 12.2 | 12.4 | 12.0 | |
![]() |
More Pharmaceuticals Company Quarterly Results: PFIZER NEULAND LABS FULFORD INDIA STRIDES PHARMA SCIENCE NATCO PHARMA
Compare DISHMAN PHARMA With: PFIZER NEULAND LABS FULFORD INDIA STRIDES PHARMA SCIENCE NATCO PHARMA
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.
Ajit Dayal on how India's vaccine strategy will impact the markets.
In this video I tell you the three Nifty ETFs I think are the best.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More